– Positive Phase 2b data from RE-THINC ESRD study of fesomersen in patients on hemodialysis presented at Kidney Week 2022 – Ionis to regain rights to fesomersen from Bayer CARLSBAD, Calif. , Nov. 4, 2022 /PRNewswire/ — Ionis Pharmaceuticals, Inc.
Ionis to hold third quarter 2022 financial results webcast
CARLSBAD, Calif. , Oct. 26, 2022 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced a live webcast on Wednesday, November 9 th at 11:30 a.m. Eastern Time to discuss its financial results for the third quarter of 2022. The webcast may be accessed at
Ionis announces plan for new manufacturing facility in Oceanside, Calif.
Larger facility will significantly increase Ionis’ development chemistry and manufacturing capabilities Sudberry Properties will build the facility and lease to Ionis for 20-plus years; Ionis retains option to renew and right of first offer to purchase the property CARLSBAD, Calif. , Oct.
Ionis provides update on development program evaluating PCSK9 antisense medicine for the treatment of hypercholesterolemia
ION449 (AZD8233) met primary endpoint in Phase 2b SOLANO study for patients with hypercholesterolemia ION449 will not advance into Phase 3 development based on pre-specified criteria CARLSBAD, Calif. , Sept. 23, 2022 /PRNewswire/ — Ionis Pharmaceuticals, Inc.
Ionis presents positive results from Phase 3 NEURO-TTRansform study at International Symposium on Amyloidosis
Ionis and AstraZeneca’s eplontersen demonstrated a statistically significant and clinically meaningful change from baseline for co-primary and secondary endpoints at 35 weeks compared to the external placebo group Eplontersen achieved an 81.2% reduction in the co-primary endpoint of serum